Valence-Logo
Beliebt
Anmelden
Loading data for ALVO — first visit, this takes a few seconds.

Zur Watchlist hinzufügen

Alvotech

NasdaqGM: ALVO · Echtzeitkurs · USD
3.95
+0.07 (1.80%)
Zum Schluss: Aug 18, 2026, 8:00 PM

Alvotech (ALVO) Stock Price, Analysis & Data

1.80%

Keine Daten verfügbar

Geld2.7
Marktkapitalisierung1.34 Mrd
Umsatz (TTM)562.04 Mio
Nettogewinn (TTM)-80.73 Mio
Beta0.18
EPS (ttm)-0.29
KGV (TTM)n/a
Forward-KGV15.89
KBV (TTM)-4.37
KUV (TTM)2.38
Earnings DateAug 19, 2026
Brief4.74
Volumen675,393
Ø Vol. (20D)863,314
Eröffnung3.92
Vortagesschluss3.88
Tagesspanne3.83 - 4.00
52-Wk Range2.94 - 9.25
Analystn/a
Kurszieln/a
Dividendenn/a
Ex-Dividenden-Datumn/a

Über ALVO

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing s...

[Mehr lesen]
Branche Drug Manufacturers - Specialty & Generic
Sektor Healthcare
IPO Datum Jun 16, 2022
Mitarbeiter 1,279
Börse NasdaqGM
Tickersymbol ALVO
Website https://www.alvotech.com
Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Alvotech 586.32 Mio, ein Anstieg von 19.74% im Vergleich zum Vorjahr (489.68 Mio). Der Gewinn lag bei 27.92 Mio, ein Rückgang von -112.04 %.

Finanzberichte

Gewinnüberraschung

Alvotech hat die Quartalszahlen am May 5, 2026 veröffentlicht:
  • Umsatz von $105.86 Mio verfehlt die Erwartungen um $0, mit -20.26% Rückgang im Jahresvergleich.
  • EPS von -0.09 verfehlt die Erwartungen um -0.02, mit 62.50% Wachstum im Jahresvergleich.

    • Nächste Ergebnisveröffentlichung

    Alvotech wird voraussichtlich die Quartalszahlen veröffentlichen am Aug 19, 2026, nach Börsenschluss.
    Analysten erwarten einen Umsatz von ... Upgrade
    news image

    vor 1 Woche · Zacks

    X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

    X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    vor 1 Woche · Zacks

    Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates

    Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -3.90% and +6.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    vor 2 Wochen · Zacks

    Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates

    Harmony Biosciences (HRMY) delivered earnings and revenue surprises of +31.96% and +3.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    vor 1 Monat · Simply Wall St.

    Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering

    Alvotech stock is coming off a difficult stretch, with the share price down about 64% over the past five years, yet the broader valuation checks currently lean toward the shares looking cheap on sever...

    news image

    vor 1 Monat · Simply Wall St.

    Alvotech’s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO)

    Alvotech recently amended its credit agreement to add a new US$75 million term loan facility led by GoldenTree Asset Management, following a US$165 million equity raise in June 2026, giving the compan...

    Seite 1 von 2